2014年1-7月，医药行业运行呈现以下特点：一是受大部分企业完成新版GMP认证和我国经济发展模式转变影响，医药行业固定资产投资增速继续下滑；二是医药行业积极转型，加大研发投入，加之外部环境有所改善，医药行业工业增加值稳定增长；三是由于医药终端增长低于预期，医药零售增速继续下滑；四是随着我国医药企业转型升级的推进，以及欧美经济的缓慢复苏，出口订单情况改善，我国医药外贸好转迹象明显；五是受内外需求增长乏力、医保控费、环保支出增大等因素的影响，医药行业收入和利润增速放缓。

报告从新能源、新材料、节能环保、生物等方面进行了分析评论。

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

报告从医药行业事件分析、竞争环境、竞争对手、行业数据等几个方面进行了分析评论。

《中国工业报》报道，目前，我国已经成为继美国和日本后世界第三大医疗器械市场，但目前我国医疗器械仍面临着较大的问题，如高端市场被国外品牌垄断、国内行业极度分散、产品技术水平低端等。 8月15日，国家食品药品监督管理总局在京召开医疗器械“五整治”专项行动阶段性总结视频会议。国家食品药品监督管理总局副局长焦红要求，各地要总结经验，进一步深化整治；要狠抓案件查办，巩固专项行动成果；要加强法规制度建设，创新监管举措；要结合新《医疗器械监督管理条例》的宣贯，不断提高医疗器械监管水平。

Parkinson’s disease is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra. This lowers the concentration of dopamine in the striatum by 80 percent. This decrease in dopamine levels leads to symptoms associated with Parkinson’s disease such as tremors, bradykinesia, and muscular rigidity. It is usually diagnosed at the age of 60; however, earlier incidence has been reported. Based on the severity, it can be categorized into the early-stage, mid-stage, and late-stage disease. Currently, approved therapies provide only symptomatic relief for the disease. Levodopa is the standard drug for the treatment of Parkinson’s disease;however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson’s disease patients under certain circumstances.

Retinal vein occlusion is the blockage of retinal veins leading to the blockage of blood flow in the retina. This disease is likely to affect individuals suffering from hypertension, diabetes mellitus,or hyperlipidemia. Retinal vein occlusion is one of the most common vascular disorders, as well as one of the most common causes of blindness in diabetic retinopathy patients. There are two types of retinal vein occlusion: central retinal vein occlusion and branch retinal vein occlusion. Central retinal vein occlusion can further be divided into ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion.

SNP genotyping is the screening and analysis of genetic variations of SNPs in the genome of various species. SNPs are commonly present in all species including humans. SNP genotyping and analysis technology can analyze thousands of SNPs and has the potential for wholegenome genotyping. It is the most common genetic variation that occurs in the genetic makeup. It is an emerging field in life science, which provides an in-depth analysis of SNPs. It is generally used by researchers for genomics study. It has a broad range of applications in several industries such as Pharmaceuticals and Pharmacogenomics, Diagnostics Research, Agriculture Biotechnology, and Breeding and Animal Livestock. There are several technologies which are used for SNP genotyping and analysis such as SNP GeneChips and microarrays, TaqMan allelic discrimination, SNP by pyrosequencing, SNPlex, and MassARRAY MALDI-TOF.

Ovarian cancer is the eighth most common cancer in women and is the fifth leading cause of cancer death, with an age-adjusted rate of 8.2 deaths per 100,000 women. Given current age-specific incidence and demographic projections, the number of cases of ovarian cancer will almost double over the next 35 years as women born between 1946 and 1964 (the baby boom generation) reach the age of highest incidence (60 years and older). While advances in surgery, chemotherapy, and radiation therapy over the past 20 years have led to improved outcomes, overall 5-year survival is only 42 percent for ovarian cancer compared with 88 percent for breast cancer and 63 percent for colorectal cancer. The high mortality rate in women with ovarian cancer is largely attributed to the later stage at presentation compared with other common cancers. This has led to intense research efforts to identify effective screening strategies for ovarian cancer, but results have been disappointing, particularly with regard to decreases in mortality. The objective of this report was to estimate the overall balance of harms and benefits from the potential use of oral contraceptives (OCs) for the primary prevention of ovarian cancer.

Ovarian cancer is the eighth most common cancer in women and is the fifth leading cause of cancer death, with an age-adjusted rate of 8.2 deaths per 100,000 women. Given current age-specific incidence and demographic projections, the number of cases of ovarian cancer will almost double over the next 35 years as women born between 1946 and 1964 (the baby boom generation) reach the age of highest incidence (60 years and older). While advances in surgery, chemotherapy, and radiation therapy over the past 20 years have led to improved outcomes, overall 5-year survival is only 42 percent for ovarian cancer compared with 88 percent for breast cancer and 63 percent for colorectal cancer. The high mortality rate in women with ovarian cancer is largely attributed to the later stage at presentation compared with other common cancers. This has led to intense research efforts to identify effective screening strategies for ovarian cancer, but results have been disappointing, particularly with regard to decreases in mortality. The objective of this report was to estimate the overall balance of harms and benefits from the potential use of oral contraceptives (OCs) for the primary prevention of ovarian cancer.